The company has previously received allowances of broad claims surrounding the use of its Ii-Key hybrid technology platform. Both applications relate to vaccines designed using this platform, which
These product candidates – two GITR agonists and a CTLA-4 antagonist – target cell-surface checkpoint proteins that control immune responses. They are part of Agenus’ recent acquisition of
Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen. The inclusion of Soltamox on the Medicare Part D Formulary allows broad,
At the ChanTest headquarters in Cleveland, Ohio, the company has expanded its physical footprint by more than 50%. The laboratory expansion reflects the importance of providing high quality
Through partnership with Seoul National University Hospital (SNUH), the new Asian office is located within the SNUH Clinical Trials Center. This enables Celerion and its clients access to
This patent provides protection until 2031, not including any patent term extension. The patent complements Synageva’s existing and planned global patent portfolio covering its LAL deficiency program, which
Xenetic, in collaboration with the Massachusetts Life Sciences Center (MLSC) and the Massachusetts Biotechnology Council (MassBio), will host a grand opening and ribbon cutting ceremony to celebrate the
Results were presented in two poster presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) meeting in Boston. The first poster, entitled Immune Function and Viral Load
The first of the webinars, all presented by Covance’s industry experts, will promote better writing skills for specific audiences. "Commercial challenges and benefits of integrated writing services", will
The company’s name will be changed to Taxus Cardium Pharmaceuticals Group in connection with the strategic collaboration. The strategic collaboration is designed to support the commercial development of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.